Literature DB >> 22321359

Imaging modalities in high-grade gliomas: pseudoprogression, recurrence, or necrosis?

I Caroline1, M A Rosenthal.   

Abstract

High grade gliomas (HGG) frequently recur regardless of treatment. Radiological detection of progressive disease (PD) is challenging due to the possibility of therapy-related MRI changes including: pseudoprogression (PP) and radiation necrosis (RN). Both may mimic PD. We undertook a literature review to examine existing data regarding imaging modalities and their ability to distinguish between PP, RN and PD. The review revealed 26 articles comparing the value of imaging modalities used to differentiate PP, RN and PD. Overall, conventional MRI and (18)fluorine-fluorodeoxyglucose positron emission tomography ((18)F-FDG PET) were more sensitive, while thallium single photon emission CT (SPECT) was more specific in differentiating PD from PP and RN. However, further prospective studies comparing the clinical utility of MRI, PET, and SPECT are needed to establish the most reliable diagnostic tool for the differentiation of PP, RN and PD in HGG.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22321359     DOI: 10.1016/j.jocn.2011.10.003

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  13 in total

1.  A prognostic model based on preoperative MRI predicts overall survival in patients with diffuse gliomas.

Authors:  A Hilario; J M Sepulveda; A Perez-Nuñez; E Salvador; J M Millan; A Hernandez-Lain; V Rodriguez-Gonzalez; A Lagares; A Ramos
Journal:  AJNR Am J Neuroradiol       Date:  2014-01-23       Impact factor: 3.825

Review 2.  Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas.

Authors:  Nathalie L Albert; Michael Weller; Bogdana Suchorska; Norbert Galldiks; Riccardo Soffietti; Michelle M Kim; Christian la Fougère; Whitney Pope; Ian Law; Javier Arbizu; Marc C Chamberlain; Michael Vogelbaum; Ben M Ellingson; Joerg C Tonn
Journal:  Neuro Oncol       Date:  2016-04-21       Impact factor: 12.300

3.  Late post-treatment radiographic changes 3 years following chemoradiation for glioma: the importance of histopathology.

Authors:  Joao R Galante; Fausto Rodriguez; Stuart A Grossman; Roy E Strowd
Journal:  CNS Oncol       Date:  2017-07-18

Review 4.  Current concepts and challenges in the radiologic assessment of brain tumors in children: part 2.

Authors:  Benita Tamrazi; Kshitij Mankad; Marvin Nelson; Felice D'Arco
Journal:  Pediatr Radiol       Date:  2018-09-13

5.  Radiation necrosis of the pons after radiotherapy for nasopharyngeal carcinoma: diagnosis and treatment.

Authors:  Matthew N DeSalvo
Journal:  J Radiol Case Rep       Date:  2012-07-01

6.  Differentiation of tumor progression from pseudoprogression in patients with posttreatment glioblastoma using multiparametric histogram analysis.

Authors:  J Cha; S T Kim; H-J Kim; B-J Kim; Y K Kim; J Y Lee; P Jeon; K H Kim; D-S Kong; D-H Nam
Journal:  AJNR Am J Neuroradiol       Date:  2014-03-27       Impact factor: 3.825

Review 7.  Current Clinical Brain Tumor Imaging.

Authors:  Javier E Villanueva-Meyer; Marc C Mabray; Soonmee Cha
Journal:  Neurosurgery       Date:  2017-09-01       Impact factor: 4.654

8.  Small increases in enhancement on MRI may predict survival post radiotherapy in patients with glioblastoma.

Authors:  Cecelia Elizabeth Gzell; Helen R Wheeler; Philip McCloud; Marina Kastelan; Michael Back
Journal:  J Neurooncol       Date:  2016-02-15       Impact factor: 4.130

9.  (11)C-choline PET/CT tumor recurrence detection and survival prediction in post-treatment patients with high-grade gliomas.

Authors:  Wanhu Li; Li Ma; Xiaoyue Wang; Jujie Sun; Suzhen Wang; Xudong Hu
Journal:  Tumour Biol       Date:  2014-09-03

10.  Survival after radiation therapy for high-grade glioma.

Authors:  Joana Spaggiari Marra; Guilherme Paulão Mendes; Gerson Hiroshi Yoshinari; Flávio da Silva Guimarães; Suleimy Cristina Mazin; Harley Francisco de Oliveira
Journal:  Rep Pract Oncol Radiother       Date:  2018-10-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.